Arcagy/ Gineco Group
Clinical trials sponsored by Arcagy/ Gineco Group, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New trial tests drug combo to keep ovarian cancer at bay Results expected Feb 2027 (estimated)
- Weekly chemo boost could help ovarian cancer patients who Don't respond to standard treatment Results expected Jun 2027 (estimated)
- New hope for rare, deadly gynecologic cancers: drug combo trial launches Results expected Jun 2027 (estimated)
-
Immunotherapy duo takes on cervical cancer in new trial
Disease control OngoingThis Phase 2 trial tests whether adding relatlimab to nivolumab (both immunotherapy drugs) works better than nivolumab alone for locally advanced cervical cancer. About 77 women with stage IIB to IVA cervical cancer will receive either the combination or nivolumab alone before st…
Phase 2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Immunotherapy drug dostarlimab takes on chemo in advanced endometrial cancer trial
Disease control OngoingThis phase 3 trial compares the immunotherapy drug dostarlimab with standard chemotherapy in 260 women with advanced or recurrent endometrial cancer that has a specific DNA repair defect (MMR deficient). The goal is to see if dostarlimab can better delay cancer progression and im…
Phase 3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC